Researchers found that miR-133b levels were significantly lower in FAP-associated Desmoid tumors than in sporadic Desmoid tumors, while SIRT1 mRNA levels were up-regulated. A negative correlation between miR-133b and SIRT1 was observed, suggesting a novel mechanism underlying progression of FAP-associated Desmoid tumor.
The study investigates the cooperative effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in mice. The authors demonstrate that pRB has the strongest cooperative function with PTEN in suppressing Pit NETs and Menin and TRP53 in suppressing Pan NETs.
The study developed a reliable method for creating porcine hepatocellular carcinoma cells, which exhibited similar characteristics to human HCC cells. The Oncopig model was shown to be a valuable tool for testing innovative therapeutic modalities and correlative studies for new therapies.
A case series reports 5 patients developing type 1 diabetes after receiving immunotherapy, with rapid onset and serious risk for diabetic ketoacidosis. Monitoring glycemia does not predict diabetes occurrence, and GAD antibodies are present in half of these cases, warranting further investigation.
This study reveals that hypoxic exosomes promote sphere formation and stem-like phenotype in EWS cells by delivering enriched miR-210. The knockdown of HIF-1α led to decreased exosomal miR-210 levels, while inhibition of miR-210 attenuated sphere formation.
Researchers have identified NRXN1, a cell adhesion molecule, as a potential target for antibody-drug conjugate (ADC) therapy in small cell lung cancer. The study found that targeting NRXN1 with ADCs exhibited anti-tumor activity in SCLC cells.
The study provides a comprehensive analysis of current clinical trials in pancreatic cancer, revealing that most trials focus on immunotherapy, chemotherapy, and radiation. The authors conclude that these approaches have yet to strongly impact the disease, emphasizing the need for new discoveries and biomarkers.
Researchers discovered that combining an ATM inhibitor with a histone deacetylase inhibitor increases apoptosis and decreases p21 expression, allowing for more effective cancer treatment. The study found that the ATM inhibitor nullifies the HDAC inhibitor's ability to induce p21, leading to synergistic effects.
Researchers found GATA3 and APOBEC3B overexpressed in adrenocortical carcinoma, regulating cell proliferation and DNA damage. Their expression levels are linked to patient survival, providing novel insights into ACC prognosis.
The BEACON CRC trial demonstrated a survival advantage for patients with chemo-refractory BRAF mutant CRC treated with the combination of BRAF inhibitor encorafenib and EGFR inhibitor cetuximab. PLX8394, a paradox-breaker BRAF inhibitor, showed comparable efficacy to encorafenib in reducing pathway reactivation.
L-Grb2 antisense oligodeoxynucleotide (L-Grb2) has promising antitumor activity in preclinical models of ovarian and uterine carcinoma, reducing angiogenesis and increasing apoptosis. L-Grb2's therapeutic efficacy suggests a potential new target for cancer treatment.
Researchers used imaging mass spectrometry and immunohistochemistry to identify novel lipid and protein tumor markers for head and neck squamous cell carcinoma. These markers, including S100A8 and S100A9, show promise as potential diagnostic tools and may provide insights into the pathophysiology of HNSCC.
Researchers found that TMEM165 expression levels alter N-linked glycosylation, promoting the invasion and growth of breast cancer cells. This study suggests a novel role for TMEM165 as a driver of tumor invasion and identifies it as a potential biomarker for breast carcinoma.
Researchers have developed a 3D bioprinted skin model of cutaneous squamous cell carcinoma (cSCC) to test the efficacy of chemotherapies. The model selectively killed cSCC cells while sparing normal keratinocytes, demonstrating its potential for pre-clinical screening.
Researchers utilized a computational method to analyze the CDR3 regions of T-cell receptors from high-grade serous ovarian cancers. The study found that patients with low T-cell infiltration but diverse or focused repertoires had clinical outcomes similar to highly-infiltrated tumors. The authors identified the degree of divergence bet...
This study developed a hemolysis correction equation to improve serum Neuron-specific enolase (NSE) concentration accuracy in small-cell lung cancer diagnostics. The corrected results showed an increased AUC and lower cut-off value for SCLC detection, indicating the importance of hemolysis correction.
Researchers discovered two possible mechanisms that drive varying degrees of susceptibility and resistance to EMT, a key process in cancer metastasis and therapy resistance. The study's findings suggest that epigenetic feedback and stochastic partitioning during cell division contribute to this resistance.
PRRT is an approved treatment modality for gastroenteropancreatic neuroendocrine tumours, particularly in midgut NETs. In Australia, PRRT is used more widely than previously thought, despite limited Phase III trial data for lung NETs.
Researchers found that IQGAP1 controls centrosome function and defines molecular variants of breast cancer. IQGAP1 modulates nuclear-centrosome crosstalk to regulate cell division, suggesting a common target for personalized medicine in triple-negative breast cancer.
Research found that miR-133b levels were significantly lower in FAP-associated Desmoid tumors than in sporadic Desmoid tumors. SIRT1 mRNA levels were up-regulated in FAP-associated Desmoid tumor, suggesting a novel mechanism underlying progression.
A recent randomized controlled trial found that landiolol hydrochloride administration reduced the incidence of postoperative atrial fibrillation after esophagectomy for esophageal cancer. However, this did not impact overall survival in patients with esophageal cancer.
Researchers characterized bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma patients, finding distinct differences compared to healthy controls. Unique interactions between fungal and bacterial communities may serve as potential screening tool for HNSCC.
Research finds that tumor suppressor p53 influences insulin receptor gene expression in breast cancer cells, with mutant p53 strongly stimulating INSR promoter activity. This study highlights the complex interplay between p53 and the INSR pathway, with implications for breast cancer treatment.
This study defines the mutation profile of SUM in Caucasians using next-generation sequencing-based genomic analysis, identifying frequently mutated genes. The most abundant mutations were found in KIT and NRAS, while BRAF was only present in 3% of cases, providing insights into the genetics of subungual melanoma.
Indoximod increases T cell proliferation by modulating CD4+ T cells via the aryl hydrocarbon receptor and reactivating mTOR. It also downregulates IDO protein expression in dendritic cells, opposing the immunosuppressive effects of IDO and TDO.
Researchers found that BI-D1870 inhibits AML cell proliferation and increases G2/M population without affecting CDC2 and CDC25C. The combination of BI-D1870 and vincristine synergistically increases mitotic arrest and apoptosis in AML cells, providing a promising novel approach to overcoming resistance.
This study evaluated the relationship between preoperative Geriatric Nutritional Risk Index and long-term outcomes in elderly gastric cancer patients. The results showed that the GNRI is a useful prognostic indicator for estimating overall survival, cancer-specific survival, and postoperative outcomes.
Researchers report a case of hyperprogression in metastatic renal cell carcinoma patients treated with immunotherapy combinations, highlighting the need for biomarker development and treatment strategies. Cabozantinib shows promise in controlling hyperprogression, but clinical trials are needed to identify optimal approaches.
A study published in Oncotarget reports that adoptive cell therapy in combination with checkpoint inhibitors improves T cell fold expansion and increases CD8 T cell tumor reactivity in patients with late-stage metastatic ovarian cancer. The authors suggest that combination immunotherapy may be a way forward for this purpose.
miR-151a regulates endothelial cell motility and angiogenesis, with Slug expression required for these functions, providing new insights into the processes in the lung niche environment. The study highlights the potential of miR-151a as a therapeutic target against lung cancer.
A single-center retrospective study of 282 patients with early or locally advanced lung adenocarcinoma found that EGFR-mutated lung cancer had increased rates of metastatic recurrence. Early identification of these recurrences is crucial, given the improved post-relapse survival observed in this population.
A study found that survivin positivity by IHC correlates with shorter survival in Neuroendocrine tumors. Radiation exposure increases BIRC5 gene expression, which is associated with an inferior survival. Survivin long peptide-mimic vaccine shows promise in preclinical studies.
A study published in Oncotarget found that physical activity can modulate miRNAs involved in breast cancer progression, leading to reduced cancer cell viability. The researchers identified two specific miRNAs, miR-206 and anti-miR-30c, which showed promising results as non-invasive biomarkers for breast cancer prevention.
A study published in Oncotarget found that T-DM1 significantly improves response rates and median progression-free survival in patients with HER2 positive metastatic breast cancer. This suggests a preferred second-line choice for T-DM1 over trastuzumab emtansine.
An exploratory study found that metformin combined with rapamycin was well-tolerated in patients with stable or responding metastatic pancreatic ductal adenocarcinoma (mPDA) after 6 months of chemotherapy. The combination was associated with exceptionally long survival rates and improved disease stability.
A study found that loss of p16 expression is associated with shortened overall survival in esophageal cancer patients, while high Ki67 labeling index is an independent prognosticator of poor survival. Rare homozygous 9p21 deletions can lead to complete loss of p16 expression.
Researchers analyzed ATAC-seq data from 404 cancer patients to correlate chromatin accessibility with tumor characteristics, age, sex, and survival rates. The study found that chromatin accessibility on the X chromosome is strongly dependent on patient sex, but not on age or tumor stage.
The study found that combinations of paclitaxel (PAC) and withaferin A (WFA) are highly synergistic against human non-small cell lung cancer cells, showing greater sensitivity than either treatment alone. WFA was active against PAC-sensitive and PAC-resistant NSCLC cells, demonstrating its potential therapeutic efficacy.
This study found that HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) cells exhibit enhanced radiosensitivity and increased cell motility after radiation therapy. In contrast, HPV-negative OPSCC cells show decreased radiosensitivity and reduced cell motility.
The iPS87 cell line is characterized as a cancer-inducing, stem cell-like cell line that can be used to develop novel treatments for prostate cancer. After 8 transfers, the cultured cells lost their tumor-inducing capability and stem cell marker expression.
Researchers found that roscovitine enhances nuclear enrichment of certain signaling molecules and promotes differentiation in leukemia cells treated with all-trans retinoic acid (ATRA). This novel mechanism reveals new therapeutic vulnerabilities and basic molecular features of ATRA-induced differentiation.
Researchers found that overexpression of hPCL3S promotes proliferation, anchorage-independent growth, and migration in human LNCaP prostate cancer cells. Silencing of endogenous hPCL3S in DU145 and PC3 prostate cancer cells impairs these effects.
Researchers found that plasma monitoring by RT-PCR-based EGFR mutation test can rapidly identify NSCLC patients resistant to osimertinib treatment due to different types of mutations. The study suggests that fluctuating levels of EGFR sensitizing mutations in plasma reflect tumor burden.
Researchers found that DOT1L inhibition significantly reduces MM cell viability in vitro and inhibits xenograft growth in mice. Concomitant targeting of SETD1B enhances this effect, suggesting a novel therapeutic angle for cancer treatment.
A preclinical study characterized quizartinib's binding affinity and selectivity for FLT3, demonstrating its high affinity and preclinical antitumor activity against midostaurin-resistant AML cells. The study aims to evaluate the role of quizartinib in treating relapsed or refractory AML patients.
Researchers developed a microRNA-based signature that predicts local-regional failure and overall survival in patients with pancreatic cancer. The four-miRNA risk score provides prognostic information for clinical outcomes after surgical resection.
The Oncotarget review explores the use of biomarkers, CA19-9, gemcitabine-abraxane, FOLFIRINOX, and other treatments to identify patients who benefit most from therapy in pancreatic cancer. Further studies are needed to better understand pancreatic cancer biology and improve prognosis.
A recent study published in Oncotarget found that microRNA (miR) dysregulation is associated with immune cell activation, gastric inflammation, and carcinogenesis. Specifically, miR-155 upregulation is considered a key marker of chronic gastric inflammation and predisposes patients to gastric carcinogenesis.
Research found statistically associated CpG sites were analyzed in blood samples from atherothrombotic stroke cohorts, revealing differences in DNA methylation status of MMP24 between stable and unstable carotid plaques. The study suggests a correlation between DNA methylation patterns and plaque instability.
Establishing an inducible BCL6 knock-out model allows studying the phenotype of BCL6 loss in DLBCL xenografts in vivo. The study demonstrates significant tumor growth inhibition and initial tumor stasis followed by slow tumor growth kinetics upon treatment with BCL6 degraders.